Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1631-1635.
doi: 10.21037/tlcr-23-273. Epub 2023 Jun 12.

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

Shruti R Patel  1 , Joel W Neal  1
Affiliations
Editorial

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

Shruti R Patel et al. Transl Lung Cancer Res. .
No abstract available

Keywords: ADAURA; Osimertinib; adjuvant; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-273/coif). JWN received grants or contracts from AbbVie, Novartis, Merck, Genentech/Roche, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Janssen, Adaptimmune, GSK, and consulting fees from AstraZeneca, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, Summit Therapeutics, Novocure, Genentech/Roche, AbbVie, Takeda Pharmaceuticals, Jounce Therapeutics, Novartis, and Exelixis. SRP has no conflicts of interest to declare.

Comment on

References

    1. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1-iv21. 10.1093/annonc/mdx222 - DOI - PubMed
    1. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 2019;94:1623-40. 10.1016/j.mayocp.2019.01.013 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-57. 10.1016/S0140-6736(21)02098-5 - DOI - PubMed
    1. He J, Huang Z, Han L, et al. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol 2021;59:90. 10.3892/ijo.2021.5270 - DOI - PMC - PubMed